# Riluzole Orodispersible Film Replicate Bioavailability

> **NCT04819438** · PHASE1 · COMPLETED · sponsor: **Cross Research S.A.** · enrollment: 54 (actual)

## Conditions studied

- Healthy Participants

## Interventions

- **DRUG:** Riluzole 50 mg orodispersible film
- **DRUG:** Rilutek® 50 mg riluzole tablets

## Key facts

- **NCT ID:** NCT04819438
- **Lead sponsor:** Cross Research S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-15
- **Primary completion:** 2021-03-14
- **Final completion:** 2021-03-14
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2025-05-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04819438

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04819438, "Riluzole Orodispersible Film Replicate Bioavailability". Retrieved via AI Analytics 2026-07-31 from https://api.ai-analytics.org/clinical/NCT04819438. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*